Synthesis and antimalarial evaluation of novel isocryptolepine derivatives
dc.contributor.author | Whittell, Louise | |
dc.contributor.author | Batty, Kevin | |
dc.contributor.author | Wong, R. | |
dc.contributor.author | Bolitho, Erin | |
dc.contributor.author | Fox, Simon | |
dc.contributor.author | Davis, T. | |
dc.contributor.author | Murray, Paul | |
dc.date.accessioned | 2017-01-30T15:13:08Z | |
dc.date.available | 2017-01-30T15:13:08Z | |
dc.date.created | 2011-11-27T20:00:51Z | |
dc.date.issued | 2011 | |
dc.identifier.citation | Whittell, Louise R. and Batty, Kevin T. and Wong, Rina P.M. and Bolitho, Erin M. and Fox, Simon A. and Davis, Timothy M.E. and Murray, Paul E. 2011. Synthesis and antimalarial evaluation of novel isocryptolepine derivatives. Bioorganic & Medicinal Chemistry. 19 (24): pp. 7519-7525. | |
dc.identifier.uri | http://hdl.handle.net/20.500.11937/44272 | |
dc.identifier.doi | 10.1016/j.bmc.2011.10.037 | |
dc.description.abstract |
A series of mono- and di-substituted analogues of isocryptolepine have been synthesized and evaluated for in vitro antimalarial activity against chloroquine sensitive (3D7) and resistant (W2mef) Plasmodium falciparum and for cytotoxicity (3T3 cells). Di-halogenated compounds were the most potent derivatives and 8-bromo-2-chloroisocryptolepine displayed the highest selectivity index (106; the ratio of cytotoxicity (IC50 = 9005 nM) to antimalarial activity (IC50 = 85 nM)). Our evaluation of novel isocryptolepine compounds has demonstrated that di-halogenated derivatives are promising antimalarial lead compounds. | |
dc.publisher | Elsevier | |
dc.title | Synthesis and antimalarial evaluation of novel isocryptolepine derivatives | |
dc.type | Journal Article | |
dcterms.source.volume | 19 | |
dcterms.source.startPage | 7519 | |
dcterms.source.endPage | 7525 | |
dcterms.source.issn | 0968-0896 | |
dcterms.source.title | Bioorganic & Medicinal Chemistry | |
curtin.department | School of Pharmacy | |
curtin.accessStatus | Fulltext not available |